[go: up one dir, main page]

SG11201810935SA - Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid bearing carboxylate charges and hydrophobic radicals - Google Patents

Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid bearing carboxylate charges and hydrophobic radicals

Info

Publication number
SG11201810935SA
SG11201810935SA SG11201810935SA SG11201810935SA SG11201810935SA SG 11201810935S A SG11201810935S A SG 11201810935SA SG 11201810935S A SG11201810935S A SG 11201810935SA SG 11201810935S A SG11201810935S A SG 11201810935SA SG 11201810935S A SG11201810935S A SG 11201810935SA
Authority
SG
Singapore
Prior art keywords
basal insulin
acid bearing
carboxylate charges
bearing carboxylate
injectable solution
Prior art date
Application number
SG11201810935SA
Inventor
Alexandre Geissler
Ségolène LAAGE
Richard Charvet
Olivier Soula
Original Assignee
Adocia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adocia filed Critical Adocia
Publication of SG11201810935SA publication Critical patent/SG11201810935SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN HAVING A PI OF BETWEEN 5.8 AND 8.5 AND A COPOLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS [0001] The invention relates to physically stable compositions in the form of an injectable aqueous solution, the pH of which is from 6.0 to 8.0, comprising at least: a) a basal insulin of which the isoelectric point (pI) is from 5.8 to 8.5, and b) a co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical.
SG11201810935SA 2016-06-07 2017-06-07 Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid bearing carboxylate charges and hydrophobic radicals SG11201810935SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1655222A FR3052072A1 (en) 2016-06-07 2016-06-07 PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A CO-POLYAMINOACIDE CARRYING CARBOXYLATE LOADS AND HYDROPHOBIC RADICALS
PCT/EP2017/063865 WO2017211903A1 (en) 2016-06-07 2017-06-07 Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid bearing carboxylate charges and hydrophobic radicals

Publications (1)

Publication Number Publication Date
SG11201810935SA true SG11201810935SA (en) 2019-01-30

Family

ID=57348773

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201810937WA SG11201810937WA (en) 2016-06-07 2017-06-07 Injectable solution at ph 7, comprising at least one basal insulin whose pi is between 5.8 and 8.5, a prandial insulin and/or a gastrointestinal hormone, and a copolyamino acid bearing carboxylate charges and hydrophobic radicals
SG11201810935SA SG11201810935SA (en) 2016-06-07 2017-06-07 Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid bearing carboxylate charges and hydrophobic radicals

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201810937WA SG11201810937WA (en) 2016-06-07 2017-06-07 Injectable solution at ph 7, comprising at least one basal insulin whose pi is between 5.8 and 8.5, a prandial insulin and/or a gastrointestinal hormone, and a copolyamino acid bearing carboxylate charges and hydrophobic radicals

Country Status (12)

Country Link
US (2) US10548952B2 (en)
EP (2) EP3463293B1 (en)
JP (1) JP2019517555A (en)
CN (2) CN109640953B (en)
BR (2) BR112018075151A2 (en)
EA (2) EA039363B1 (en)
FR (1) FR3052072A1 (en)
MX (2) MX2018015067A (en)
PH (1) PH12018502558B1 (en)
SA (2) SA518400588B1 (en)
SG (2) SG11201810937WA (en)
WO (2) WO2017211916A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3070264A1 (en) * 2017-08-24 2019-03-01 Adocia PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN INCLUDING AN INHIBIT OF 5.8 TO 8.5 AND A CO-POLYAMINOACIDE CARBOXYLATE AND HYDROPHOBIC RADICAL CARRIERS
FR3083089A1 (en) * 2018-06-29 2020-01-03 Adocia PH 7 INJECTION SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A CO-POLYAMINOACID CARRYING CARBOXYLATES AND HYDROPHOBIC RADICALS
EP3740195A1 (en) * 2017-12-07 2020-11-25 Adocia Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
WO2019110773A1 (en) 2017-12-07 2019-06-13 Adocia Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
BR112020011570A2 (en) 2017-12-07 2020-12-08 Adocia SOLUTION INJECTABLE AT A PH 7 UNDERSTANDING AT LEAST A BASAL INSULIN PRESENTING A PI BETWEEN 5.8 AND 8.5 AND A CO-POLYAMINO ACID CONTAINING CARBOXYLATE AND HYDROPHOBIC RADICAL LOADS
FR3083086A1 (en) * 2018-06-29 2020-01-03 Adocia COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AMYLINE, AN AMYLINE RECEPTOR AGONIST OR AN AMYLINE ANALOG AND A CO-POLYAMINOACID
MA51600A (en) 2017-12-07 2020-11-25 Adocia COMPOSITIONS IN THE FORM OF AN AQUEOUS SOLUTION FOR INJECTION CONSISTING OF AMYLINE, AN AMYLINE RECEPTOR AGONIST OR ANALOGUE OF AMYLINE AND A CO-POLYAMINOACID
WO2019115411A1 (en) * 2017-12-07 2019-06-20 Adocia Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analogue and a copolyamino acid
MX2020005916A (en) 2017-12-07 2020-10-19 Adocia Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid.
US11633460B2 (en) 2017-12-07 2023-04-25 Adocia Injectable solution at pH 7 comprising at least one basal insulin wherein the pI is comprised from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
FR3067247A1 (en) * 2018-06-07 2018-12-14 Adocia COMPOSITIONS IN THE FORM OF AN INJECTION AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINOACID
WO2019243628A1 (en) * 2018-06-22 2019-12-26 Adocia Injectable composition with a ph of 7 comprising a co-polyaminoacid bearing carboxylate charges and hydrophobic radicals and at least one basal insulin having at least a prandial effect and a basal effect
FR3084585B1 (en) * 2018-08-03 2020-11-06 Adocia SOLUTION FOR INJECTION AT PH 7 INCLUDING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 AND AN AMPHIPHILIC COMPOUND CARRIER OF HYDROPHOBIC RADICALS
FR3084586B1 (en) * 2018-08-03 2020-11-06 Adocia COMPOSITIONS IN THE FORM OF AN AQUEOUS SOLUTION FOR INJECTION CONSISTING OF AMYLINE, AN AMYLINE RECEPTOR AGONIST OR ANALOGUE OF AMYLINE AND AN AMPHIPHILIC COMPOUND CARRIER OF HYDROPHOBIC RADICALS
WO2020115334A1 (en) * 2018-12-07 2020-06-11 Adocia Method for preparing a stable composition in the form of an injectable aqueous solution
US20200179489A1 (en) * 2018-12-07 2020-06-11 Adocia Injectable solution at ph 7 comprising at least one basal insulin which pi is from 5.8 to 8.5 and a co-polyamino-acid bearing carboxylate charges and hydrophobic radicals and a limited amount of m-cresol
WO2020245470A1 (en) 2019-06-07 2020-12-10 Adocia Injectable solution at ph 7 containing at least one basal insulin, the pi of which is between 5.8 and 8.5, liraglutide, and a copolyamino acid carrying carboxylate charges and hydrophobic radicals

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3482551D1 (en) 1983-10-26 1990-07-26 Kanebo Ltd PROTEIN-CONTAINING EMULSIFIER, THE PRODUCTION THEREOF AND THE EMULSIFIED COSMETIC COMPOSITION CONTAINING THEM.
DE3837825A1 (en) 1988-11-08 1990-05-10 Hoechst Ag NEW INSULIN DERIVATIVES, THEIR USE AND A PHARMACEUTICAL PREPARATION CONTAINING THEM
FR2801226B1 (en) 1999-11-23 2002-01-25 Flamel Tech Sa COLLOIDAL SUSPENSION OF SUBMICRONIC PARTICLES FOR VECTORIZATION OF ACTIVE INGREDIENTS AND METHOD OF PREPARATION
CZ2004710A3 (en) 2001-12-20 2005-02-16 Eli Lilly And Company Insulin compound exhibiting protracted activity
FR2840614B1 (en) 2002-06-07 2004-08-27 Flamel Tech Sa POLYAMINOACIDS FUNCTIONALIZED BY ALPHA-TOCOPHEROL AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
BRPI0409600A (en) 2003-04-29 2006-04-18 Lilly Co Eli insulin analog, composition, method of treating hyperglycemia, and proinsulin analogue
FR2862535B1 (en) * 2003-11-21 2007-11-23 Flamel Tech Sa PHARMACEUTICAL FORMULATIONS FOR PROLONGED RELEASE OF INTERLEUKINS AND THEIR THERAPEUTIC APPLICATIONS
FR2915683B1 (en) * 2007-05-03 2009-08-07 Flamel Technologies Sa SELF-PRECIPITANT PHARMACEUTICAL FORMULATIONS FOR MODIFIED RELEASE OF ACTIVE INGREDIENTS
JP5950477B2 (en) 2011-08-10 2016-07-13 アドシア Injection solution of at least one basal insulin
FR2985429B1 (en) 2012-01-09 2016-07-29 Adocia PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A SUBSTITUTED POLYAMINOACID OBTAINED BY A CONTROLLED POLYMERIZATION PROCESS
CN113730555A (en) * 2012-01-09 2021-12-03 阿道恰公司 Injectable solution of basal insulin and substituted copoly (amino acid) having pH7 and at least PI 5.8 to 8.5
FR3001896B1 (en) 2013-02-12 2015-07-03 Adocia PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WHERE THE ISO-ELECTRIC POINT IS BETWEEN 5.8 AND 8.5 AND A HYDROPHOBIC ANIONIC POLYMER
FR3001895B1 (en) 2013-02-12 2015-07-03 Adocia PH7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WHERE THE ISOELECTRIC POINT IS INCLUDED IN 5.8 AND 8.5 AND AN ANIONIC COMPOUND CARRYING CARBOXYLATE LOADS AND HYDROPHOBIC RADICALS

Also Published As

Publication number Publication date
EA039363B1 (en) 2022-01-18
FR3052072A1 (en) 2017-12-08
BR112018075151A2 (en) 2019-03-26
MX2018015068A (en) 2019-05-09
PH12018502558B1 (en) 2024-02-02
EA201892736A1 (en) 2019-05-31
EP3463292B1 (en) 2020-08-05
CN109640953B (en) 2021-10-29
EP3463292A1 (en) 2019-04-10
CN109379888B (en) 2021-10-29
WO2017211916A1 (en) 2017-12-14
CN109379888A (en) 2019-02-22
CN109640953A (en) 2019-04-16
US20170348423A1 (en) 2017-12-07
EP3463293B1 (en) 2021-05-12
SA518400596B1 (en) 2022-03-16
BR112018075140A2 (en) 2019-03-26
US10383920B2 (en) 2019-08-20
SG11201810937WA (en) 2019-01-30
JP2019517555A (en) 2019-06-24
US20170348396A1 (en) 2017-12-07
WO2017211903A1 (en) 2017-12-14
EA201892737A1 (en) 2019-05-31
EP3463293A1 (en) 2019-04-10
PH12018502558A1 (en) 2019-10-14
MX2018015067A (en) 2019-05-09
US10548952B2 (en) 2020-02-04
EA039333B1 (en) 2022-01-14
SA518400588B1 (en) 2022-03-07

Similar Documents

Publication Publication Date Title
SA518400588B1 (en) Injectable Solution at PH 7 Comprising at Least One Basal Insulin The PI of Which is From 5.8 to 8.5 and A Co-Polyamino Acid Bearing Carboxylate Charges and Hydrophobic Radicals
MX2025009746A (en) Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
SG11201810939PA (en) Compositions in the form of an injectable aqueous solution, comprising human glucagon and an end-grafted copolyamino acid
WO2019110797A8 (en) Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
SG11202005322RA (en) Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
MA46245A (en) CYCLIC DINUCLEOTIDES AS AGONISTS (INTERFERON GENE STIMULATOR)
PH12020550828A1 (en) Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
IL275148A (en) Injectable solution with a ph of 7 comprising at least one basal insulin with a pi of between 5.8 and 8.5 and a co-polyaminoacid bearing carboxylate charges and hydrophobic radicals
MX2014001190A (en) Injectable solution of at least one type of basal insulin.
PH12016500377A1 (en) Polypeptide for the hydrolytic cleavage of zearalenone and/or zearalenone derivatives, isolated polynucleotide thereof, and additive containing polypeptide, use of said polypeptide and method
MY182507A (en) Aqueous ophthalmic solution
MX2025008231A (en) Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
MX2015015162A (en) Uric acid level lowering agent.
PH12017502319A1 (en) Injectable pharmaceutical formulations of lefamulin
EP3502119A3 (en) Immunomodulating beta-1,6-d-glucans
MX2016004328A (en) IMMUNOPOTENCER.
MX2018016339A (en) Anti-infective heterocyclic compounds and uses thereof.
FR3074681B1 (en) PH 7 INJECTION SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A CO-POLYAMINOACID CARRYING CARBOXYLATES AND HYDROPHOBIC RADICALS
MX2020006670A (en) Aqueous composition comprising 2-(dimethyl-1h-pyrazole-1-yl) succinic acid and ammonia.
SG11201804902UA (en) A composition for improving memory, learning ability, and cognitive ability
FR3083088B1 (en) SOLUTION FOR INJECTION AT PH 7 INCLUDING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 AND A CO-POLYAMINOACID CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS
EA202091387A1 (en) COMPOSITIONS IN THE FORM OF INJECTED AQUEOUS SOLUTION CONTAINING HUMAN GLUCAGON AND COPOLYAMINO ACID
PL410126A1 (en) Method for obtaining a suspension of chitosan-silver nanoparticles and chitosan-silver nanocomposite
UA94395U (en) A method of producing of a stabilized solution baced on decamethoxin and hyaluronic acid having therapeutic activity
UA116653C2 (en) APPLICATION OF MEANS OF BATH BIRDS FOR THE CONTROL OF PEST INSECTS